NDA 209606 · Bristol Myers Squibb
Idhifa
Enasidenib Mesylate · Oral
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jan 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Aug 1, 2017
Approved uses
2
Original approval plus efficacy supplements
Registered trials
47
4 Phase 3, 12 recruiting
FAERS reports
3,369
2,076 serious, 839 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DIFFERENTIATION SYNDROME Patients treated with IDHIFA have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . WARNING: DIFFERENTIATION SYNDROME See full prescribing information for complete boxed warning. Patients treated with IDHIFA have experienced symptoms of differentiation syndrome, which can be fatal if not treated. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring...
What it is approved for
From the label in effect Jan 16, 2025.
IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test ( 1.1 ). 1.1 Acute Myeloid Leukemia IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.
Mechanism: Enasidenib is a small molecule inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme. Enasidenib targets the mutant IDH2 variants R140Q, R172S, and R172K at approximately 40-fold lower concentrations than the wild-type enzyme in vitro. Inhibition of the mutant IDH2 enzyme by enasidenib led to decreased 2-hydroxyglutarate (2-HG) levels and induced myeloid differentiation in vitro and in vivo in mouse xenograft models of IDH2 mutated AML. In blood samples from patients with AML with mutated IDH2, enasidenib decreased 2-HG levels, reduced blast counts and increased percentages of mature...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 24, 2020 Supplement 4 · Efficacy · priority review OrphanLabelLetter
- Aug 1, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
2 products under this application
- IDHIFA · ENASIDENIB MESYLATE EQ 100MG BASE · TABLET, ORAL · Prescription
- IDHIFA · ENASIDENIB MESYLATE EQ 50MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Enasidenib" as an intervention, any sponsor and status, largest first.
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPivotal-lookingRecruiting
Beat AML, LLCAcademic, hospital or other
NCT03013998 · 3,000 participants (planned) · Start Nov 2016 · Primary completion Dec 2032
Drug: Samalizumab (BAML-16-001-S1); BI 836858 (BAML-16-001-S2) and 45 more · For: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 31 sites in all
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
- A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive ChemotherapyPivotal-lookingActive, not recruiting
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT03839771 · 968 participants (planned) · Start Mar 1, 2019 · Primary completion Apr 17, 2027
Drug: AG-120; Placebo for AG-120 and 2 more · For: Acute Myeloid Leukemia; Myelodysplastic Syndrome With Excess Blasts-2
Sites: Adelaide, Australia; Brisbane, Australia; Camperdown, Australia · 181 sites in all
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT02813135 · 472 participants (planned) · Start Aug 3, 2016 · Primary completion Feb 2031
Drug: Ribociclib; Topotecan and 22 more · For: Pediatric Cancer
Sites: Copenhagen, Denmark; Villejuif, France; Angers, France · 23 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT01915498 · 345 participants · Start Aug 27, 2013 · Primary completion Jul 25, 2019
Drug: Enasidenib · For: Hematologic Neoplasms
Sites: Duarte, California; Stanford, California; Aurora, Colorado · 24 sites in all
- An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT02577406 · 319 participants · Start Dec 30, 2015 · Primary completion Mar 17, 2020
Drug: AG-221; Azacitidine and 2 more · For: Leukemia, Myeloid; Isocitrate Dehydrogenase
Sites: Miami, Florida; Orlando, Florida; Chicago, Illinois · 93 sites in all
- Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT04603001 · 260 participants (planned) · Start Nov 19, 2020 · Primary completion Jul 3, 2023
Drug: LY3410738; Venetoclax and 1 more · For: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myelomonocytic Leukemia (CMML) and 1 more
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 37 sites in all
- Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 MutationActive, not recruiting
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT02632708 · 153 participants · Start Dec 31, 2015 · Primary completion Dec 13, 2018
Drug: AG-120; AG-221 and 5 more · For: Newly Diagnosed Acute Myeloid Leukemia (AML); Untreated AML; AML Arising From Myelodysplastic Syndrome (MDS) and 2 more
Sites: Duarte, California; Los Angeles, California; Aurora, Colorado · 17 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death682
- off label use246
- fatigue224
- nausea197
- hospitalisation186
- diarrhoea142
- platelet count decreased133
- decreased appetite121
- acute myeloid leukaemia119
- drug ineffective102
- asthenia92
- full blood count decreased81
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 90 |
| 2018 | 400 |
| 2019 | 424 |
| 2020 | 548 |
| 2021 | 395 |
| 2022 | 317 |
| 2023 | 372 |
| 2024 | 377 |
| 2025 | 276 |
| 2026 | 170 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Idhifa (Enasidenib Mesylate)
2024 spending
$185M
Beneficiaries
1,016
5,462 claims
Per beneficiary
$181,791
$1,106.63 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $75,226,515 |
| 2021 | $78,791,111 |
| 2022 | $93,705,063 |
| 2023 | $118,905,343 |
| 2024 | $184,699,247 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Stein EM, DiNardo CD, Pollyea DA, et al. · Blood 2017 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Stein EM, DiNardo CD, Fathi AT, et al. · Blood 2021 · Clinical Trial, Phase I, Multicenter Study
- Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
de Botton S, Montesinos P, Schuh AC, et al. · Blood 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML.
Alhajahjeh A, Patel KK, Shallis RM, et al. · Leuk Lymphoma 2025 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.
Fathi AT, Kim HT, Soiffer RJ, et al. · Blood Adv 2022 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.
Richard-Carpentier G, Gupta G, Koraksic C, et al. · Lancet Haematol 2025 · Clinical Trial, Phase I, Multicenter Study
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.